This inventor holds 3 USPTO granted patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2022-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022-2025
Title: Jinxing Li: Pioneering Innovation in Medicine
Introduction:
Jinxing Li, a visionary inventor based in Kanagawa, Japan, is dedicated to pushing the boundaries of technology to create a better future. With a passion for innovation, Li stands out as a true pioneer in the world of inventors.
Latest Patents:
With a remarkable total of 2 patents under his belt, Jinxing Li's most recent groundbreaking inventions focus on heterocyclic compounds with HDAC6 inhibitory action. These compounds have the potential to revolutionize the treatment of central nervous system diseases, particularly neurodegenerative conditions. The compounds described by Li have vast implications for the development of novel medications.
Career Highlights:
Jinxing Li's innovative work is carried out at Takeda Pharmaceutical Company Limited, a prominent player in the pharmaceutical industry known for its cutting-edge research and development. His affiliation with Takeda underscores his commitment to driving innovation within a renowned and forward-thinking organization.
Collaborations:
In his pursuit of innovative breakthroughs, Jinxing Li collaborates closely with esteemed colleagues at Takeda Pharmaceutical Company Limited. Among his notable coworkers are Masahiro Ito and Takeshi Yamamoto, with whom he works hand in hand to further advance the boundaries of pharmaceutical innovation.
Conclusion:
Jinxing Li's dedication to advancing medical technology through his inventive creations places him at the forefront of innovation in the field of pharmaceuticals. His relentless pursuit of excellence and his commitment to improving the lives of individuals affected by central nervous system diseases truly mark him as a visionary inventor with a profound impact on the industry.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
